You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
GLP-1s could be the product that pushes Hims & Hers over the edge to mainstream adoption.
Hims & Hers (HIMS -1.24%) has been a great growth stock since coming public, but it's now starting to turn a profit. In this video, Travis Hoium highlights the company's financials and why the launch of GLP-1 medications could be a game-changer.
*Stock prices used were end-of-day prices of May 20, 2024. The video was published on May 21, 2024.
Travis Hoium has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Travis Hoium is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through their link, they will earn some extra money that supports their channel. Their opinions remain their own and are unaffected by The Motley Fool.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
